Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Products under Development by Stage of Development | 8 | 1 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Products under Development by Therapy Area | 9 | 1 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Products under Development by Indication | 10 | 1 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Products under Development by Companies | 13 | 2 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Products under Development by Universities/Institutes | 15 | 2 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Companies Involved in Therapeutics Development | 23 | 7 |
| Advaxis, Inc. | 23 | 1 |
| Aeterna Zentaris Inc. | 24 | 1 |
| Bavarian Nordic A/S | 25 | 1 |
| Curevac AG | 26 | 1 |
| GenSpera, Inc. | 27 | 1 |
| Inovio Pharmaceuticals, Inc. | 28 | 1 |
| OncBioMune Pharmaceuticals Inc. | 29 | 1 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Drug Profiles | 30 | 26 |
| ADXS-PSA Drug Profile | 30 | 4 |
| AEZS-120 Drug Profile | 34 | 2 |
| Cellular Immunotherapy to Target PSA for Prostate Cancer Drug Profile | 36 | 1 |
| Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer Drug Profile | 37 | 1 |
| CV-9103 Drug Profile | 38 | 2 |
| CV-9104 Drug Profile | 40 | 2 |
| G-114 Drug Profile | 42 | 1 |
| G-115 Drug Profile | 43 | 1 |
| INO-5150 Drug Profile | 44 | 1 |
| Prostatac Drug Profile | 45 | 3 |
| rilimogene galvacirepvec Drug Profile | 48 | 5 |
| Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer Drug Profile | 53 | 1 |
| Vaccine to Target PSA and HMWMAA for Prostate Cancer Drug Profile | 54 | 2 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Dormant Projects | 56 | 1 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Discontinued Products | 57 | 1 |
| Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Featured News &Press Releases | 58 | 11 |
| Jul 20, 2016: Pre-Clinical Research Supports Additional Studies of OncBioMune Technology for Breast Cancer Vaccine | 58 | 1 |
| Jul 13, 2016: OncBioMune Submits Protocol to Initiate Phase 2/3 Trial of ProscaVax for Prostate Cancer | 58 | 1 |
| Jun 14, 2016: OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches | 59 | 1 |
| Jun 02, 2016: Mexican Regulatory Authorities Supportive of OncBioMunes Phase 2 of ProscaVax for Prostate Cancer | 59 | 1 |
| May 18, 2016: Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer | 60 | 1 |
| May 11, 2016: OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer | 61 | 1 |
| May 04, 2016: OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer | 62 | 1 |
| Apr 28, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China | 63 | 1 |
| Apr 12, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Hong Kong | 63 | 1 |
| Apr 05, 2016: Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts | 64 | 1 |
| Mar 16, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Europe | 65 | 1 |
| Feb 23, 2016: OncBioMune Continuing Phase 1 Trial, While Initiating Phase 2 Trial of ProscaVax for Prostate Cancer | 65 | 1 |
| Dec 16, 2015: FDA Lifts Advaxis Clinical Hold On ADXS-PSA | 66 | 1 |
| Nov 10, 2015: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China and Ukraine | 66 | 1 |
| Aug 05, 2015: Advaxis's ADXS-PSA Awarded Research Grants From the Prostate Cancer Foundation and the Movember Foundation | 67 | 2 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |